- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03431766
0.2% Chx Gel vs Implant Bacterial Contamination
February 12, 2018 updated by: Michele Paolantonio, G. d'Annunzio University
A Prospective, Randomized-controlled Study of the Effect of a Chlorhexidine Based Gel on the Internal Implant Surface Treatment on the Reduction of Bacterial Load and on the Regressive Bone Modelling.
The objective of this human randomized, double blind, placebo-control (RDBPC) study is to evaluate the efficacy of a 0.2% chlorhexidine (CHX) gel on reducing bacterial load and peri-implant inflammation at implant-abutment interface during the early healing stage.Thirty-six healthy patients (mean age 52,28 years; range 29-75 years) without a significant past medical anamnesis, all non-smokers, will be recruited as candidates for single implant placement and prosthetic rehabilitation.Patients will be randomly divided in group A (control) and group B (test) as indicated by the randomization chart.
All Implants (Cortex classic, Shalomi, Israel)would be inserted by two skilled operators who followed a two-stage protocol and placed them according to the manufacturer's instructions.Eventually, all patients will be rehabilitated with a single implant-supported crown.
During all the stages either a gel containing 0.20% CHX (Plak ®Gel; Polifarma Wellness Srl, Rome, Italy) or a placebo gel (Placebo, Polifarma Wellness Srl, Rome, Italy) will be used.
The two gels are perfectly alike in packaging, color and smell and nobody knew the exact location of placebo or test gel, which will be revealed, only after data collection would be performed, by the person who prepared them.
A or B gel will be placed on the internal connection abutments and then a cover screw would be inserted.
Finally, the site would be sutured with non-absorbable nylon sutures.
Cone Beam Computed Tomography evaluation (CBCT) (VatechIpax 3D PCH-6500, Fort Lee, NJ USA) would be performed both for pre-operative and post-surgical implant placement.
Both gels will be given to the patients, according to the protocol, and applied 2 times/day until suture removal after 7 days.
Soft tissue biopsies would be performed by means of a circular scalpel (5.5 mm in diameter) at the implant insertion (T0) and after two months of healing (second stage surgery)(T1) to analyze the peri-implant inflammatory infiltrate and the micro-vessel density (MVD) in both groups.
All the radiographs taken during the study time points would be analysed to measure the bone resorption after 1 year or on other studt time points.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The objective of this human randomized, double blind, placebo-control (RDBPC) study is to evaluate the efficacy of a 0.2% chlorhexidine (CHX) gel on reducing bacterial load and peri-implant inflammation at implant-abutment interface during the early healing stage.
Thirty-six healthy patients (mean age 52,28 years; range 29-75 years) without a significant past medical anamnesis, all non-smokers, will be recruited as candidates for single implant placement and prosthetic rehabilitation.Patients will be randomly divided in group A (control) and group B (test) as indicated by the randomization chart.
The randomization of this prospective, randomized-controlled, double blind study was obtained using computer generated random numbers, centralized with sequentially sealed opaque envelopes provided by the study adviser.The surgeon will open the sealed envelope containing the randomized group only after having inserted the implant.During the first evaluation, all subjects will be clinically examined: radiographs, plaque and bleeding scores would be carried out for diagnostic evaluation; then the patients would be scheduled for surgery procedures.
All Implants (Cortex classic, Shalomi, Israel) would be inserted by two skilled operators who will follow a two-stage protocol and would place them according to the manufacturer's instructions.
Before surgery all the patients would be subject to applications of chlorhexidine digluconate solution 0.2% for 2 minutes to obtain lower bacterial load and local anesthesia would be given with Articaine® (Ubistesin 4% - Espe Dental AG Seefeld, Germany) associated with epinephrine (1:100.000).
Eventually, all patients would be rehabilitated with a single implant-supported crown.
During all the stages either a gel containing 0.20% CHX (Plak ®Gel; Polifarma Wellness Srl, Rome, Italy) or a placebo gel (Placebo, Polifarma Wellness Srl, Rome, Italy) would be used.
The two gels are perfectly alike in packaging, colour and smell and nobody knows the exact location of placebo or test gel, which would be revealed, only after data collection would be performed, by the person who prepared them.
A or B gel would be placed on the internal connection abutments and then a cover screw would be inserted.
Finally, the site would be sutured with non-absorbable nylon sutures.
Cone Beam Computed Tomography evaluation (CBCT) (VatechIpax 3D PCH-6500, Fort Lee, NJ USA) would be performed both for pre-operative and post-surgical implant placement.
All patients will recieve antibiotic therapy, 2g/day for 6 days (Augumentin®; Glaxo-Smithkline Beecham, Brentford, UK).The post-operative pain would be controlled with NSAIDs, and oral hygiene instructions would be given.
Both gels would be given to the patients, according to the protocol, and applied 2 times/day until suture removal after 7 days.
Soft tissue biopsies would be performed by means of a circular scalpel (5.5 mm in diameter) at the implant insertion (T0) and after two months of healing (second stage surgery)(T1) to analyze the peri-implant inflammatory infiltrate and the micro-vessel density (MVD) in both groups.
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: bruna sinjari, dds, phd
- Phone Number: +393927471479
- Email: b.sinjari@unich.it
Study Locations
-
-
CH
-
Chieti, CH, Italy, 66100
- Recruiting
- G. d'Annunzio University
-
Contact:
- sergio caputi, MD; DDS
- Phone Number: +393927471479
- Email: scaputi@unich.it
-
Principal Investigator:
- Sergio caputi, md; dds
-
Sub-Investigator:
- bruna sinjari, dds, phd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients of both sex between 18 and 75 years,
- good systemic and oral health,
- need of single crown implant supported restoration,
- at least six months of healing after tooth extraction,
- cortical bone thickness > 5 mm measured by means of a cone beam computed tomography (CBCT).
Exclusion Criteria:
- poor oral hygiene,
- active periodontal disease or other oral disorders,
- insufficient bone thickness for implant insertion,
- bone augmentation procedures,
- immediate loading protocols,
- uncontrolled diabetes mellitus,
- immune diseases,
- smoking
- bruxism.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: control group A
on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
|
On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
|
Experimental: test group B
on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
|
On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
bone resorption around dental implants on both study groups
Time Frame: 1 year after implant placement
|
The bone resorption will be measured on periapical radiographs that would be taken during the clinical phases of the study.
It would be used also an individual bite block to assure the reproducibility of the same position during all the phases.
The distance between the crestal bone level and the first point where the bone attaches to the implant will be measured.
The measurements will be in millimetres.
|
1 year after implant placement
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiological quantitative evaluation, bacteria count cfu/ml
Time Frame: 3 months after implant placement
|
to assess the presence of the specifical periodontal pathogens, pophyromonas gingivalis all the helaing abutment of the patients in both groups would be taken instad of throuing away and a qualitative analysis will be done on the department of microbiology of the same university.
|
3 months after implant placement
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sergio caputi, MD, DDS, g. d'annunzio chieti-pescara university
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 17, 2015
Primary Completion (Anticipated)
January 12, 2019
Study Completion (Anticipated)
June 30, 2019
Study Registration Dates
First Submitted
January 15, 2018
First Submitted That Met QC Criteria
February 12, 2018
First Posted (Actual)
February 13, 2018
Study Record Updates
Last Update Posted (Actual)
February 13, 2018
Last Update Submitted That Met QC Criteria
February 12, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2342
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Resorption
-
Cairo UniversityUnknown
-
Second Affiliated Hospital, School of Medicine,...RecruitingAlveolar Bone ResorptionChina
-
Aristotle University Of ThessalonikiUniversity Paul Sabatier of ToulouseRecruiting
-
Nourhan M.AlyAlexandria UniversityCompletedMandibular Bone ResorptionEgypt
-
Marmara UniversityCompleted
-
Egyptian Russian UniversityCompletedAlveolar Bone ResorptionEgypt
-
Cairo UniversityUnknown
-
International Advanced Dentistry, LisbonUnknownBone Loss | Alveolar Bone Resorption
-
University of LouisvilleBioHorizons, Inc.RecruitingAlveolar Bone ResorptionUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompleted
Clinical Trials on placebo gel
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHealthyUnited States, Puerto Rico
-
NutravaliaSlb PharmaCompletedOverweight and ObesityFrance
-
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.Recruiting
-
Population CouncilCompletedHIV InfectionUnited States
-
Topokine Therapeutics, Inc.SuspendedExcess Submental Fat ("Double Chin")
-
Xinnate ABRegion SkaneCompletedBlister | Epidermolysis Bullosa | Wound of Skin | Varicose Ulcer of Lower LimbSweden
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
Kalypsys, Inc.CompletedNeuropathic Pain | Herpes Zoster | Postherpetic Neuralgia | ShinglesUnited States
-
Suzhou Kintor Pharmaceutical Inc,CompletedAcne Vulgaris | Androgenetic AlopeciaUnited States